Comments on "High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence"

J Med Virol. 2024 Oct;96(10):e29950. doi: 10.1002/jmv.29950.
No abstract available

Keywords: B/F/TAF; HIV; adherence; black patients; drug resistance; switch.

Publication types

  • Letter

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / therapeutic use
  • Adult
  • Anti-HIV Agents* / therapeutic use
  • Black or African American
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Drug Combinations
  • Drug Resistance, Viral*
  • Emtricitabine / therapeutic use
  • HIV Infections* / drug therapy
  • HIV Infections* / virology
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use
  • Humans
  • Medication Adherence / statistics & numerical data
  • Piperazines / therapeutic use
  • Pyridones / therapeutic use
  • Tenofovir / analogs & derivatives
  • Tenofovir / therapeutic use
  • Treatment Outcome
  • United States

Substances

  • Adenine
  • Anti-HIV Agents
  • bictegravir, emtricitabine, tenofovir alafenamide, drug combination
  • Bridged Bicyclo Compounds, Heterocyclic
  • Drug Combinations
  • Emtricitabine
  • Heterocyclic Compounds, 3-Ring
  • Heterocyclic Compounds, 4 or More Rings
  • Piperazines
  • Pyridones
  • Tenofovir
  • tenofovir alafenamide